FGF17
FGF17 (fibroblast growth factor 17)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Fgf17, Fibroblast growth factor 17
The factor identified when young cerebrospinal fluid was infused into aged mouse brains. In humans it is known for a different reason: FGF17 mutations cause congenital hypogonadotropic hypogonadism.
Overview
A 2022 Nature paper took a different route into the young-blood question by asking about cerebrospinal fluid rather than plasma, on the reasoning that CSF is the immediate environment of brain cells. Infusing young CSF directly into aged mouse brains improved memory function. Transcriptome analysis of the hippocampus found oligodendrocytes to be the most responsive cell type, and young CSF boosted oligodendrocyte progenitor cell proliferation and differentiation both in the aged hippocampus and in primary cultures. Metabolic labelling of nascent messenger RNA identified serum response factor as the mediator, and screening CSF for activators of that factor identified FGF17. Infusing FGF17 alone was sufficient to induce progenitor proliferation and long-term memory consolidation in aged mice, and blocking it impaired cognition in young mice.
A 2026 Neurotherapeutics paper reported that FGF17 targets neuronal survival and oligodendrogenesis together to restore deficits after stroke, again in animals.
The human record for FGF17 is genuine and substantial, and it is about something else entirely. In 2013, sequencing of 386 unrelated individuals with congenital hypogonadotropic hypogonadism and 155 controls identified mutations in FGF17 among several genes in the FGF8 signalling pathway, alongside IL17RD, DUSP6, SPRY4 and FLRT3. Congenital hypogonadotropic hypogonadism and its anosmia-associated form, Kallmann syndrome, are developmental disorders of GnRH neuron biology. That is human FGF17 data of good quality, and it says that losing FGF17 function during development causes a reproductive and olfactory disorder. It says nothing about giving FGF17 to an older adult.
No human has received FGF17. There is no registered trial.
Mechanism of action
In mice, young cerebrospinal fluid boosts oligodendrocyte progenitor proliferation and differentiation in the aged hippocampus through serum response factor, a transcription factor driving actin cytoskeleton rearrangement whose expression falls with age in hippocampal progenitors. FGF17 was identified by screening CSF for activators of that pathway, and FGF17 infusion alone induced progenitor proliferation and long-term memory consolidation in aged mice while FGF17 blockade impaired cognition in young mice. In humans, the established biology is developmental: FGF17 is part of the FGF8 signalling group that patterns the mid-hindbrain boundary and the frontal cortex, and loss-of-function mutations cause congenital hypogonadotropic hypogonadism. Nothing links the mouse hippocampal mechanism to a human outcome.
Human evidence
No human has received FGF17. The human evidence is genetic: loss-of-function mutations in FGF17 have been identified in people with congenital hypogonadotropic hypogonadism, a developmental disorder of reproduction and olfaction. That is real human data about FGF17 and it is not about ageing.
- American Journal of Human Genetics 2013: 386 unrelated individuals with congenital hypogonadotropic hypogonadism and 155 controls were sequenced across seven candidate genes in the FGF8 signalling group. Mutations in FGF17 were found among affected individuals, alongside IL17RD, DUSP6, SPRY4 and FLRT3.
- No interventional human study of FGF17 exists for any indication, and no trial is registered.
- No human pharmacokinetic, safety or dosing data of any kind exist for FGF17.
What this does not tell you: Genetic evidence that losing FGF17 during development causes a disorder does not tell you what giving FGF17 to an adult would do, and can easily mislead in either direction. The mouse ageing work also delivered FGF17 directly into the brain via cerebrospinal fluid, which is not a route available for a chronic human treatment, and a growth factor infused into the central nervous system raises questions about proliferation that a memory study in aged mice is not designed to answer.
Reading the research record
FGF17 is the cleanest example in this batch of a factor whose human literature exists, is good, and is about something else. Anyone searching for FGF17 in humans will find the hypogonadotropic hypogonadism genetics, which is a well-conducted study in 386 affected individuals, and it would be easy to read that as human validation of an ageing target. It is not. It is evidence that FGF17 matters during development of the GnRH and olfactory systems.
The delivery problem is the other honest obstacle. The 2022 experiment infused young cerebrospinal fluid, and then FGF17, directly into the brain. A systemic protein that has to reach the hippocampus is a different pharmaceutical problem from an intracerebroventricular infusion in a mouse, and no work has addressed it. That is a reason the field has produced no registered trial rather than a reason the biology is wrong.
The 2026 stroke paper is worth noting because it is the first extension of this finding into an injury model with a clearer clinical endpoint than normal cognitive ageing. It remains animal work.
The evidence, charted
Fig. 1 · evidence composition
1of 4 citations (25%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2013 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Not approved
Approved in 2 of 4, prescription route in 0, not approved in 2. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2022
Young CSF restores oligodendrogenesis and memory in aged mice via Fgf17
Mouse. Infusing young cerebrospinal fluid into aged brains improved memory. Oligodendrocytes were the most responsive cell type, and young CSF boosted oligodendrocyte progenitor proliferation and differentiation in the aged hippocampus and in culture, mediated by serum response factor. FGF17 infusion alone was sufficient to induce progenitor proliferation and long-term memory consolidation in aged mice, and FGF17 blockade impaired cognition in young mice.
Nature - Animal2026
FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits
Animal. FGF17 acted on neuronal survival and oligodendrogenesis together to restore deficits in a stroke model, extending the oligodendrocyte finding beyond normal ageing into injury.
Neurotherapeutics - Human2013
Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism
Human genetics, and the main body of FGF17 data in people. Seven candidate genes in the FGF8 signalling group were sequenced in 386 unrelated individuals with congenital hypogonadotropic hypogonadism, including its anosmia-associated form Kallmann syndrome, and 155 controls. Mutations in FGF17 were identified among the affected individuals. Loss of FGF17 function during development causes a reproductive and olfactory disorder; this is not an ageing study.
American Journal of Human Genetics - Review2024
Fgf17: A regulator of the mid/hind brain boundary in mammals
Review of FGF17 biology in mammals, focused on its developmental role in patterning the mid-hindbrain boundary, which is the context in which this factor was studied for two decades before the ageing work.
Differentiation
Frequently asked questions
Has FGF17 been given to a human?
No. There is no administration study, no safety data and no registered trial of FGF17 for any indication. The mouse work delivered it directly into the brain.
What did young cerebrospinal fluid do in mice?
Infusing young CSF into aged mouse brains improved memory. Oligodendrocytes were the most responsive cell type, and FGF17 was identified as the factor that reproduced the effect on its own: infusing FGF17 induced oligodendrocyte progenitor proliferation and long-term memory consolidation in aged mice, while blocking it impaired cognition in young mice.
Is FGF17 linked to any human condition?
Yes, but not to ageing. Loss-of-function mutations in FGF17 have been identified in people with congenital hypogonadotropic hypogonadism, including its anosmia-associated form Kallmann syndrome, in a study of 386 affected individuals. That is a developmental disorder of reproduction and smell.